Ellen Rohde, Ph.D.
Vice President, Pharmacology and Toxicology
Ellen Rohde is vice president, preclinical pharmacology and toxicology at Verve Therapeutics, where she is responsible for leading a team of scientists to provide proof of concept and identify development candidates for the company’s gene editing programs. Dr. Rohde brings extensive drug development experience to Verve with a focus on translational sciences, DMPK and bioanalysis. She was an integral part of drug discovery projects for both biologics and small molecules where her activities ranged from target identification, lead identification, optimization and development up to registration. Previously, she served as senior director, pharmacokinetics and biodistribution at Intellia Therapeutics, where she oversaw discovery stage research programs for gene editing therapeutics based on CRISPR/Cas9 mechanisms. In this role, she was responsible for building the infrastructure, team and collaborations with contract research organizations in support of the company’s gene editing programs. Prior to Intellia, Dr. Rohde was director, analytical chemistry and DMPK at Cerulean Pharma. She served as associate director, preclinical DMPK at Biogen contributing to the approval of Tecfidera, a disease modifying drug for relapsing MS.
Dr. Rohde earned her master’s degree, with honors, in chemistry from the University of Leipzig, Germany, and her Ph.D. in analytical chemistry from the University of Cincinnati. She completed postdoctoral work at Abbott Laboratories and a research fellowship at the Mayo Clinic. She has authored or contributed to more than 25 papers.